ライフサイエンスコーパス: fulminant

1 lar coagulation have been reported following fulminant A. baumannii sepsis, little is known about the

2 precisely and rapidly than ICP in pigs with fulminant ALF.

3 on within the eye contributed to the rapidly fulminant and destructive course of Bacillus endophthalm

4 rior to M tuberculosis infection resulted in fulminant and disseminated disease by 8 weeks after infe

5 dolent localised papillary carcinomas to the fulminant and lethal anaplastic disease.

6 athogen Bacillus anthracis causes anthrax, a fulminant and lethal infection of mammals.

7 Delay in surgical intervention for fulminant and medically refractory cases leads to worse

8 irectly sequenced the entire HBV genome from fulminant and nonfulminant cases.

9 ms ranging from mild-to-severe diarrhoea, to fulminant and often fatal pseudomembranous colitis (PMC)

10 ans and African-Americans), characterized by fulminant and phasic insulin dependence, but lacking mar

11 nto three categories: acute mild infection, 'fulminant' and chronic hepatitis (long-term persistent f

12 Cisplatin induced fulminant apoptosis of HK-2 cells with increased caspase

13 T1 mice appear normal at baseline yet suffer fulminant apoptotic cardiomyopathy when challenged by me

14 for duration of disease, was associated with fulminant appearance (odds ratio, 1.24; 95% confidence i

15 conclude that liver damage in this model of fulminant autoimmune hepatitis is driven by CD4(+) T cel

16 whether corticosteroids improve survival in fulminant autoimmune hepatitis, drug-induced, or indeter

17 The double-deficient mice had fulminant autoimmunity in very early life and a gravely

18 Within 48 h following aortic constriction, fulminant biventricular congestive heart failure, charac

19 ATA-1 deficiency, Cdk9 inhibition produced a fulminant but reversible megakaryoblastic disorder remin

20 In our model of fulminant cardiac allograft rejection in sensitized host

21 We conducted a case-control study of fulminant (case patients) and nonfulminant (control pati

22 potential use for the management of severe, fulminant cases is discussed.

23 survivors and undetectable in all six fatal fulminant cases.

24 ho were diagnosed with severe, complicated ("fulminant") CDAD and were treated at the University of P

25 d, germ-free C57BL/6 mice are susceptible to fulminant CDI from a BI/NAP1 strain and represent a nove

26 dA and TcdB (designated "ABA") that reverses fulminant CDI in mice infected with an epidemic 027 stra

27 ith significant immunocompromise, history of fulminant CDI, or irreversible bleeding disorders were e

28 rimary amebic meningoencephalitis (PAM) is a fulminant central nervous system infection caused by the

29 NUT-variant carcinomas might have a less fulminant clinical course than those with BRD4-NUT fusio

30 with a substantially more severe and rapidly fulminant clinical course.

31 9 patients treated with TPE for an attack of fulminant CNS inflammatory demyelinating disease.

32 n that all Pros1-/- mice die in utero,from a fulminant coagulopathy and associated hemorrhages.

33 ute respiratory distress syndrome owing to a fulminant coccidioidomycosis infection that responded to

34 Trials of tacrolimus for treatment of fulminant colitis in children have been disappointing.

35 ptible mice (dnKO) that develop spontaneous, fulminant colitis, triggered by Bacteroides thetaiotaomi

36 with symptoms ranging from mild diarrhea to fulminant colitis.

37 The patient had a fulminant course leading to death within 72 h of present

38 esents the ultimate therapeutic option for a fulminant course or end-stage liver disease.

39 The patient had a fulminant course requiring emergent valve replacement.

40 ents can monitor or prevent the unexpectedly fulminant course.

41 aive male hosts, beta1AR antibodies elicited fulminant DCM at high frequency.

42 The absence of alphabeta T cells led to the fulminant death of LPS-challenged mice, coinciding with

43 ge (TPE) has been successfully used to treat fulminant demyelinating attacks unresponsive to steroids

44 and presentation ranges from asymptomatic to fulminant, depending on the characteristics of both the

45 The onset of fulminant diabetes was associated with severe lymphocyte

46 All the control animals developed fulminant disease and succumbed to the MARV challenge by

47 many questions remain, especially regarding fulminant disease associated with Plasmodium falciparum

48 an primates (NHPs) results in an accelerated fulminant disease course compared to that of naturally o

49 st that elevation of PTX3 is associated with fulminant disease during A. baumannii sepsis.

50 thy at base line or were predisposed to more fulminant disease following pressure overload stimulatio

51 at either toxin A or toxin B alone can cause fulminant disease in the hamster infection model and pre

52 ng either toxin A or toxin B alone can cause fulminant disease in the hamster model of infection.

53 All three strains produced fulminant disease in this animal with a spectrum of prog

54 This fulminant disease is caused by an ENU-induced recessive

55 eumonia and, on rare occasions, manifests as fulminant disease that leads to mortality, even in healt

56 Yersinia pestis causes bubonic plague, a fulminant disease where host immune responses are abroga

57 age chemotactic peptide-1 were indicative of fulminant disease with >90% mortality within 48 hrs.

58 he periphery, whereas clade C FIV-C36 causes fulminant disease with CD4(+) T-cell depletion and neutr

59 FV infected IFNAR(-/-) mice develop an acute fulminant disease with high viral loads leading to organ

60 festation of clinical disease and clinically fulminant disease, as well as cell infiltrate, resolved

61 reptococcus pyogenes, in addition to causing fulminant disease, can be carried asymptomatically and m

62 In fulminant disease, increased IL-1 signaling resulted in

63 In addition to causing fulminant disease, Streptococcus pyogenes may be asympto

64 y modified animals, and because they develop fulminant disease.

65 pproximately 9,000 organisms leads to acute, fulminant disease.

66 gration into the GI tract where they mediate fulminant disease.

67 cases in which patients begin treatment for fulminant disease.

68 aganglionosis in patients with end-stage or fulminant disease.

69 Four patients presented with fulminant, disseminated PTLD; only one of these four pat

70 egional burden of lesions, indicating a more fulminant dissemination of pTDP-43 pathology.

71 ganisms range from acute watery diarrhoea to fulminant dysentery characterised by frequent scant bloo

72 b blockade of both B7-1 and B7-2 resulted in fulminant, early-onset neuropathy.

73 , amnestic (1 patient), and a severe form of fulminant encephalitis (2 patients).

74 ptic (1 patient), amnestic (3 patients), and fulminant encephalitis (2 patients).

75 as and higher incidence of neuroinvasion and fulminant encephalitis seen in the young, and may also e

76 (NSV) is a neuronotropic virus that causes a fulminant encephalomyelitis in susceptible mice due to d

77 crotizing encephalopathy (ANE) presents with fulminant encephalopathy and characteristic brain lesion

78 atal lethality in mice, primarily because of fulminant epilepsy.

79 ated with disruption of colonic homeostasis, fulminant epithelial/tumor cell proliferation, and activ

80 cult to predict whether a patient with acute fulminant failure will recover spontaneously.

81 ne knockout background, POT mice developed a fulminant form of peripheral neuropathy that affected al

82 e disorders (MPDs), either transient or more fulminant forms, can also occur in infants with NS (NS/M

83 s, granulomatous fungal sinusitis, and acute fulminant fungal rhinosinusitis.

84 he course of his EBV infection and died from fulminant gram-positive bacterial sepsis.

85 The poly(U/UC) region of the fulminant HCV JFH-1 strain was a relatively weak activat

86 to be susceptible to infection with another fulminant HCV strain (JFH1).

87 iant cell myocarditis (GCM) typically causes fulminant heart failure, arrhythmias, or heart block, ne

88 lated with severe myocardial dysfunction and fulminant heart failure.

89 During human fulminant hepatic failure (FHF) circulating levels of mo

90 ce of healthy residual liver mass, otherwise fulminant hepatic failure (FHF) may arise.

91 n is the only proven effective treatment for fulminant hepatic failure (FHF), but its use is limited

92 antation (OLT) is an effective treatment for fulminant hepatic failure (FHF), but postOLT mortality i

93 Death occurs in half of all children with fulminant hepatic failure (FHF).

94 homas may involve the liver but rarely cause fulminant hepatic failure (FHF).

95 d experimental protocol of LPS-induced acute fulminant hepatic failure (i.p. injection of low dose of

96 Candidates with fulminant hepatic failure (Status-1A) receive the highes

97 on communication to prevent amplification of fulminant hepatic failure and acetaminophen-induced hepa

98 riceal bleeding, as well as in patients with fulminant hepatic failure and alcoholic hepatitis.

99 ls are beginning to acknowledge subgroups of fulminant hepatic failure and properly randomize therapy

100 ce nodularity is commonly seen at imaging in fulminant hepatic failure and usually reflects a combina

101 who was transferred to our institution with fulminant hepatic failure and worsening hepatic encephal

102 y patients who die from paracetamol overdose fulminant hepatic failure as accurately as King's Colleg

103 ars) who underwent liver transplantation for fulminant hepatic failure at our institution during a 5-

104 sinusoidal endothelium and portal tracts of fulminant hepatic failure explants, whereas there were m

105 Patients diagnosed with fulminant hepatic failure face high mortality rates.

106 s into a bioartificial liver device to treat fulminant hepatic failure improved animal survival, ther

107 er, the hepatocyte-like cells rescued lethal fulminant hepatic failure in a nonobese diabetic severe

108 ied strain HC-TN (genotype 1a), which caused fulminant hepatic failure in a patient and, subsequently

109 ansplantation were biliary atresia in seven, fulminant hepatic failure in six, chronic rejection in s

110 ute, self-limiting liver disease that causes fulminant hepatic failure in specific high-risk groups o

111 The management of patients with fulminant hepatic failure is a major clinical endeavor.

112 be included in the differential diagnosis of fulminant hepatic failure of unknown pathogenesis.

113 No fulminant hepatic failure or death was observed.

114 Patients with fulminant hepatic failure should be stabilized and trans

115 Patients meeting criteria for fulminant hepatic failure without acetaminophen toxicity

116 major complications of acute liver failure (fulminant hepatic failure) and a major cause of death in

117 liver disease ranging from acute (including fulminant hepatic failure) to chronic hepatitis, cirrhos

118 Eight (33%) patients with fulminant hepatic failure, 97 (66%) patients with chroni

119 ver transplantation if they have evidence of fulminant hepatic failure, a life-threatening systemic c

120 Patients dying of fulminant hepatic failure, for whom no alternative thera

121 Although rare, HSV-1 can also cause fulminant hepatic failure, which is often fatal.

122 ut may lead to acute hepatitis and rarely to fulminant hepatic failure.

123 traumatic brain injury, ischemic stroke, and fulminant hepatic failure.

124 pper limit of normal but almost never causes fulminant hepatic failure.

125 terial peritonitis, hepatorenal syndrome, or fulminant hepatic failure.

126 ailure is one of the few treatable causes of fulminant hepatic failure.

127 e sister presented with acute BCS leading to fulminant hepatic failure.

128 anges from mild elevations in liver tests to fulminant hepatic failure.

129 liver allotransplantation for patients with fulminant hepatic failure.

130 ped as follows: a) chronic liver failure; b) fulminant hepatic failure; c) patients immediately statu

131 eloped postembolization syndrome or signs of fulminant hepatic insufficiency after PVE or resection.

132 Many of these agents produce fulminant hepatic necrosis and, in some cases, were with

133 Fulminant hepatitis (FH) is a disease characterized by m

134 as been proposed as the etiological agent of fulminant hepatitis (FH) or hepatitis-associated aplasti

135 The two prolines (P310 and P341 of Japanese fulminant hepatitis 1 [JFH-1]) contained in these motifs

136 that the H316N mutation rendered a Japanese fulminant hepatitis 1 chimeric HCV genome encoding the g

137 human hepatocytes infected with the Japanese fulminant hepatitis 1 HCV strain as well as in biopsies

138 cells, and approximately 90% in J6/Japanese fulminant hepatitis 1 HCV-infected cells without affecti

139 icon cells, approximately 70% in J6/Japanese fulminant hepatitis 1 HCV-transfected cells, and approxi

140 were given LPS and D-galactosamine to induce fulminant hepatitis and MCC950 to specifically inhibit N

141 2000, 21 acute HBV infections, including 10 fulminant hepatitis B cases, were identified.

142 All patients with fulminant hepatitis B died (case-fatality rate = 47.6%).

143 ons previously described in association with fulminant hepatitis B.

144 Infantile fulminant hepatitis developed in 1 of 1050 children who

145 ine hepatitis virus strain-3 (MHV-3)-induced fulminant hepatitis due to excessive macrophage-dependen

146 the severity of peritoneal inflammation and fulminant hepatitis in mice.

147 duced lethality following endotoxin-mediated fulminant hepatitis in mice.

148 oimmune hepatitis can present as an acute or fulminant hepatitis in the absence of pre-existent fibro

149 nfected mice showed decreased mortality from fulminant hepatitis induced by administration of LPS or

150 In a more fulminant hepatitis induced by injecting agonistic Fas-s

151 ssential for protection against ConA-induced fulminant hepatitis since only A3R-expressing mice were

152 ore-severe acute peritoneal inflammation and fulminant hepatitis than control mice.

153 nomic replicon cells or genotype 2a Japanese fulminant hepatitis type 1 (JFH-1) virus-infected hepato

154 We show that viral production of Japanese fulminant hepatitis type 1 increases 1,000-fold when cel

155 h-titer infectious virus as well as Japanese fulminant hepatitis type 1, H77/C3, and Con1/C3.

156 f severe end-stage liver diseases and infant fulminant hepatitis were significantly lower in the vacc

157 2%) were admitted to hospital, two developed fulminant hepatitis, and one needed a liver transplant;

158 No major liver-related complications (e.g., fulminant hepatitis, decompensated liver, and hepatocell

159 Mice treated with HDAD-Ipf1 developed fulminant hepatitis, however, because of the exocrine-di

160 romoter mutant implicated in the outbreak of fulminant hepatitis, which was caused by the neighboring

161 ent populations of immune cells and Japanese fulminant hepatitis-1 (JFH-1) HCV-infected Huh7.5 (cell

162 ted/founder virus, sucrose-purified Japanese fulminant hepatitis-1 (JFH-1), a virus encoding a lucife

163 When HCV Japanese fulminant hepatitis-1 (JFH-1)-infected hepatocytes were

164 and primary human hepatocytes with Japanese fulminant hepatitis-1 (JFH1) HCV cell culture system (HC

165 The Japanese fulminant hepatitis-1 (JFH1)-based hepatitis C virus (HC

166 c HBV infection, but might prevent infantile fulminant hepatitis.

167 sig4 in mice ameliorates MHV-3-induced viral fulminant hepatitis.

168 genotype 2a strain JFH-1 from a patient with fulminant hepatitis.

169 sion, and similar mortality from Fas-induced fulminant hepatitis.

170 cessive copper accumulation in the liver and fulminant hepatitis.

171 BC, alcohol, primary biliary cirrhosis, and fulminant hepatitis.

172 also protected mice from endotoxin shock and fulminant hepatitis.

173 cetaminophen-induced liver toxicity, causing fulminant hepatocellular injury.

174 following variables: age>65 years, severe or fulminant illness (by the Horn index), and additional an

175 ef hospitalization to a rapidly progressive, fulminant illness resulting in the multiple organ dysfun

176 sfer of wt MDSCs was capable of reducing the fulminant immune-mediated liver damage in cremtg mice to

177 In humans, this fulminant infection is characterized by lung capillary l

178 This may reflect a reliance on models of fulminant infection.

179 ghly motile spirochete that causes acute and fulminant infections in humans and other accidental host

180 BV exposure, affected patients often develop fulminant infectious mononucleosis (FIM), a life-threate

181 nd often fatal, clinical sequelae, including fulminant infectious mononucleosis, hemophagocytic lymph

182 e present for Aire-deficient mice to develop fulminant infiltrates.

183 Fulminant inflammation in the liver is often accompanied

184 ial burdens that are usually associated with fulminant inflammatory disease in normal hosts.

185 manifestations ranging from simple fever to fulminant inflammatory diseases with high mortality rate

186 pression of T cells during TB as well as the fulminant inflammatory response that can compromise T-ce

187 t of influenza symptoms predicted death from fulminant influenza (P = 0.04).

188 f individuals at risk for the development of fulminant invasive CMV disease.

189 e virus, was isolated in cell culture from a fulminant lethal case of hantavirus disease presenting w

190 invasive pneumococcal infection resulting in fulminant, lethal pneumococcal sepsis.

191 ce of waiting list registration for ESLD and fulminant liver disease decreased, whereas that for HCC

192 ther) and by indication for transplantation (fulminant liver disease, hepatocellular carcinoma [HCC],

193 The patient died due to fulminant liver failure 14 months later; the histopathol

194 massive hepatocyte apoptosis and subsequent fulminant liver failure and death in D-GalN-sensitized m

195 r transplantation (LT) between patients with fulminant liver failure and those with cirrhosis and sev

196 We previously reported that acute fulminant liver failure associated with B19 virus infect

197 h is frequently up-regulated in HCCs, delays fulminant liver failure in mice by inhibiting apoptosis,

198 followed by 6 hours of reperfusion induced a fulminant liver failure in WT and Stat6 KO mice, as asse

199 SCs) protect from death in a lethal model of fulminant liver failure induced by intraperitoneal injec

200 These data suggest that fulminant liver failure may potentially benefit from tre

201 rnative medicine agents are a major cause of fulminant liver failure necessitating liver transplantat

202 ed liver injury has been described involving fulminant liver failure or death.

203 or definite AIH) among the 70 patients with fulminant liver failure was 24% for simplified criteria

204 cluding a subset of patients presenting with fulminant liver failure who required liver transplant.

205 DNA, but not control non-CpG DNA, induces a fulminant liver failure with subsequent shock-mediated d

206 nt treatment also prevents TNFalpha-mediated fulminant liver failure without affecting liver regenera

207 pression can lead to severe acute hepatitis, fulminant liver failure, and death.

208 dinedione sometimes, although rarely, led to fulminant liver failure, and ultimately the drug was rem

209 is currently the only effective therapy for fulminant liver failure, but its use is limited by the s

210 nitive treatment for end-stage cirrhosis and fulminant liver failure, but the lack of available donor

211 rosis factor (TNF)-mediated murine models of fulminant liver failure.

212 tation is wide, varying from mild disease to fulminant liver failure.

213 neurological disability, then developed sub-fulminant liver failure.

214 ed in a variety of diseases, including acute fulminant liver failure.

215 or patients with decompensated cirrhosis and fulminant liver failure.

216 and lipopolysaccharide (LPS) model of acute, fulminant liver injury dramatically decreased serum alan

217 ent mice are resistant to the development of fulminant liver injury upon lipopolysaccharide administr

218 ll three animal groups ameliorated otherwise fulminant liver injury, as evidenced by depressed serum

219 Acetaminophen (APAP) overdose causes severe, fulminant liver injury.

220 ould be beneficial clinically to limit acute fulminant liver pathologies.

221 patient who is admitted urgently with acute (fulminant) liver failure in whom consent may not be poss

222 e NZW mouse strain is phenotypically normal, fulminant lupus glomerulonephritis (GN) develops when NZ

223 in G receptor IIB (FcgammaRIIB) results in a fulminant, lupus-like disease in C57BL/6 but not BALB/c

224 not those that received 2 x 10(6), developed fulminant macrophage pneumonia with eosinophilia, Ym1 de

225 These data demonstrate that both fulminant MAS and hemophagocytosis can arise independent

226 Fulminant MAS was characterized by dramatic elevations i

227 odel of Toll-like receptor 9 (TLR-9)-induced fulminant MAS.

228 de (LOS) is a major inflammatory mediator of fulminant meningococcal sepsis and meningitis.

229 in vivo, we set up an experimental model of fulminant meningococcemia in human skin grafted SCID mic

230 ellation of findings usually associated with fulminant meningococcemia.

231 e, in collaboration with H-RAS, BMI1 induced fulminant metastatic disease in the lung using a tail ve

232 cal and environmental stressors that trigger fulminant MH and promote myopathy.

233 sceptibility and possibly contributes to the fulminant MH episode.

234 tate the loss of Ca2+ control that defines a fulminant MH event.

235 t stress at 41 degrees C invariably triggers fulminant MH in Hom, but not Het, mice within 20 min.

236 et females and 100% of the Het males develop fulminant MH within 40 min.

237 either sex and 17% of the Het males develop fulminant MH.

238 brillar beta-amyloid (Abeta) in the brain, a fulminant microglial-mediated inflammatory reaction, and

239 of antibiotic treatment in the outcome of a fulminant model of CLP.

240 fts delayed the onset and progression of the fulminant motor neuron disease typical of the rat SOD1 G

241 hich are mainly found in patients with acute fulminant multiple sclerosis with Balo's type concentric

242 cal analysis of STIM1 transgenic mice showed fulminant muscle disease characterized by myofiber necro

243 e their dramatic presentation, patients with fulminant myocarditis (FM) might have better outcome tha

244 Treatment of viral fulminant myocarditis relies on life support measures.

245 A 36-year-old woman who was hospitalized for fulminant myocarditis with biventricular failure and car

246 hat anakinra may be a suitable treatment for fulminant myocarditis.

247 BAG3-deficient animals developed a fulminant myopathy characterized by noninflammatory myof

248 es, and its targeted deletion in mice causes fulminant myopathy with early lethality.

249 in universal mortality in conjunction with a fulminant necrotizing hepatitis.

250 scular hemorrhage in the lung in addition to fulminant necrotizing pneumonia caused by massive bacter

251 However, S. bovis is capable of causing fulminant neonatal sepsis or meningitis that is indistin

252 Knockout (KO) of CSPalpha causes fulminant neurodegeneration that is rescued by alpha-syn

253 , mutant mice invariably developed a rapidly fulminant neurological decline characterized by ataxia,

254 9 has been implicated in some cases of acute fulminant non-A, non-B, non-C, non-G liver failure.

255 All eyes had a fulminant onset within the first 24 hours of cataract su

256 tion of TLR2 in MDR1A deficiency resulted in fulminant pancolitis with early expansion of CD11b(+) my

257 We present a case of fulminant Pasteurella multocida sepsis in a 66-year-old

258 own, and no effective therapies for treating fulminant pertussis exist.

259 Patients who progressed to the fulminant phase had a mortality rate of 97% (regardless

260 Despite advances in supportive care, fulminant-phase inhalational anthrax is usually fatal.

261 th effects ranging from chronic abscesses to fulminant pneumonia and septic shock, which can be rapid

262 enza virus in cynomolgus macaques results in fulminant pneumonia that rapidly progresses to acute res

263 int Y. pestis gained the ability to induce a fulminant pneumonia.

264 ate rapidly in the airways, causing a lethal fulminant pneumonia; if unexpressed, inflammation is abo

265 with bacterial growth and the development of fulminant pneumonic and septicemic plague.

266 CD14/TLR4-MD-2 receptor, helping explain the fulminant presentation of meningococcal sepsis and menin

267 A fulminant presentation that is associated with de novo r

268 The mechanisms responsible for this fulminant process remain unknown; we hypothesized that t

269 The fulminant progression of disease has been largely ascrib

270 treated patients relapse with resistance and fulminant progression.

271 EV1 and FVC decline identifies patients with fulminant, rapid deterioration and is the strongest clin

272 ressive agents were prone to more severe and fulminant recurrent disease.

273 nimals in group 1 developed vasculopathy and fulminant rejection by day 55.

274 Indeed, cardiac allografts underwent fulminant rejection in sensitized BKO, albeit with somew

275 mem function in the sensitization phase, the fulminant rejection of cardiac allografts was B-cell-ind

276 grafts on group 3 and group 4 animals led to fulminant rejection of heart and skin grafts, in contras

277 thic pneumonia." The infection may result in fulminant respiratory decompensation and shock after tra

278 sentation, ranging from silent infections to fulminant respiratory disease and dissemination.

279 that received a nonspecific vector developed fulminant SEBOV hemorrhagic fever and succumbed.

280 Clinical manifestations range from acute fulminant sepsis to chronic infection mimicking tubercul

281 e puncture (2CLP) was used to model mild and fulminant sepsis, respectively.

282 m mild dehydration due to gastroenteritis to fulminant septic shock, requires careful assessment and

283 Brazilian purpuric fever (BPF) is a fulminant septicaemic infection of young children, cause

284 associated with the development of a rapidly fulminant shock syndrome in neutropenic patients.

285 ients progress to a severe, complicated, or "fulminant" state of life-threatening systemic toxicity.

286 Patients with fulminant/subfulminant hepatic failure and primary nonfu

287 However, survival in fulminant/subfulminant hepatic failure patients was sign

288 afety and improved survival in patients with fulminant/subfulminant hepatic failure.

289 eltamucin)lpr mice developed accelerated and fulminant systemic autoimmunity with accumulation of abn

290 wide range of disease, from mild diarrhea to fulminant systemic disease.

291 is of inhalation anthrax before the onset of fulminant systemic infection.

292 Lower doses resulted in less fulminant, systemic disease and lower mortality.

293 ocytosis, is the dominant cause of anemia in fulminant TLR-9-induced MAS.

294 Disease severity varied from fulminant to minimal in accordance with the challenge do

295 hypoxia (8% O(2)), Cd73(-/-) mice manifested fulminant vascular leakage, particularly prevalent in th

296 ctile dysfunction, we treated a patient with fulminant viral myocarditis with the interleukin-1 recep

297 Mice lacking Ifitm3 display fulminant viral pneumonia when challenged with a normall

298 remission in patients with recalcitrant and fulminant, vision-threatening ocular inflammatory disord

299 and a likelihood ratio of 23 for diagnosing fulminant WD.

300 , and a likelihood ratio of 7 for diagnosing fulminant WD.